AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for April 17, 2019 meeting

IV. Secretary’s report

V. Old Business
   A. WellCare’s List of “Other Category” Contents in the PA Denials Report

VI. New Business
   A. Proposed protocol for Hereditary Angioedema (HAE) Drug Products
   B. Proposed protocol for Urea Cycle Disorder Products
   C. Proposed protocol for Chelating Agents
   D. Proposed protocol for Zolgensma® (onasemnogene abeparovec-xioi)

VII. A. Informational Highlights/Reports
     1. DXC Technology/NJ HMO 1st Quarter 2019 Prior Authorization Report
     2. Summary of DURB Action Items
     3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category)
        (b) Physician-administered/Antiviral drugs by amount paid
        (c) Report on major changes in top drugs ranking for July 2019 meeting (if any)

     B. Medication information:
        (a) Sleeping Pill Deaths Prompt FDA to Add Strict Warnings for Drugs
        (b) House lawmakers want to cut DEA waivers for buprenorphine prescriptions
        (c) FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls
            (Valsartan, Losartan, and Irbesartan)

VIII. Referenced Material
    A. Proposed protocol for calcitonin gene-related peptide (CGRP) inhibitors
    B. Proposed protocol for gout products